AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24614165 — intervention group
Group type: COMPARATOR
Intervention: Patients who experienced severe adverse drug reactions
Number of subjects: 321
Study 22471125 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-medication group (Baihui (GV 20) and Fengchi (GB 20) acupoints)
Number of subjects: 60
Study 22471125 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (Nimodipine)
Number of subjects: 60
Study 22471125 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-medication group
Number of subjects: 60
Study 19996728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 222
Study 19996728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 19167590 — intervention group
Group type: COMPARATOR
Intervention: Short-term danazol treatment (200 mg/d for 4 weeks)
Number of subjects: 15
Study 19167590 — intervention group
Group type: COMPARATOR
Intervention: Long-term danazol treatment (mean dose of 170 mg/d for >2 years)
Number of subjects: 15
Study 16920183 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) session
Number of subjects: 56
Study 16920183 — intervention group
Group type: COMPARATOR
Intervention: Standard care (advice/education)
Number of subjects: 56
Study 15500196 — intervention group
Group type: EXPERIMENTAL
Intervention: benidipine hydrochloride (4 mg/day)
Number of subjects: 85
Study 15500196 — intervention group
Group type: COMPARATOR
Intervention: amlodipine (5-7.5 mg/day)
Number of subjects: 85
Study 15500196 — intervention group
Group type: EXPERIMENTAL
Intervention: benidipine hydrochloride (4-8 mg/day)
Number of subjects: 85
Study 15500196 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 85
Study 10934910 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to suppress negative emotion
Number of subjects: 48
Study 10934910 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to enhance negative emotion
Number of subjects: 48
Study 9056051 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazabemide 100 mg twice daily
Number of subjects: 30
Study 9056051 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazabemide 350 mg twice daily
Number of subjects: 30
Study 9056051 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazabemide (100-350 mg)
Number of subjects: 30
Study 9056051 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazabemide (single and multiple doses)
Number of subjects: 30
Study 9056051 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazabemide (multiple dosing)
Number of subjects: 30
Study 8448921 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis fluid at pH 7 (D7)
Number of subjects: 16
Study 8448921 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal dialysis fluid at pH 5 (D5)
Number of subjects: 16
Study 8448921 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis fluid with 3.86% glucose (D386)
Number of subjects: 16
Study 8448921 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal dialysis fluid with 1.36% glucose (D136)
Number of subjects: 16
Study 3021189 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 10 mg
Number of subjects: 8
Study 3021189 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 30 mg
Number of subjects: 8
Study 3021189 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 8
Study 3021189 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 8
Study 3021189 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (in vivo)
Number of subjects: 8
Study 3021189 — intervention group
Group type: COMPARATOR
Intervention: Control (Thrombin)
Number of subjects: 8
Study 30398957 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed beef protein (PRO, n=8)
Number of subjects: 16
Study 30398957 — intervention group
Group type: COMPARATOR
Intervention: Nonprotein isoenergetic carbohydrate (CHO, n=8)
Number of subjects: 16
Study 29629507 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSAAF program
Number of subjects: 346
Study 29629507 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 346
Study 26338075 — intervention group
Group type: COMPARATOR
Intervention: pterygomaxillary dysjunction + saline
Number of subjects: 200
Study 26338075 — intervention group
Group type: COMPARATOR
Intervention: tuberosity separation + saline
Number of subjects: 200
Study 26338075 — intervention group
Group type: EXPERIMENTAL
Intervention: pterygomaxillary dysjunction + tranexamic acid
Number of subjects: 200
Study 26338075 — intervention group
Group type: EXPERIMENTAL
Intervention: tuberosity separation + tranexamic acid
Number of subjects: 200
Study 24837466 — intervention group
Group type: EXPERIMENTAL
Intervention: e13a2
Number of subjects: 1105
Study 24837466 — intervention group
Group type: EXPERIMENTAL
Intervention: e14a2
Number of subjects: 1105
Study 24837466 — intervention group
Group type: COMPARATOR
Intervention: Imatinib treatment
Number of subjects: 1105
Study 22092512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular two-implant overdentures (IODs)
Number of subjects: 172
Study 22092512 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete dentures (CDs)
Number of subjects: 172
Study 20528908 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib treatment (four cycles, initially as monotherapy, then combined with glucocorticoid from cycle two to four)
Number of subjects: 20
Study 20528908 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib treatment with glucocorticoid
Number of subjects: 20
Study 20528908 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib in vitro
Number of subjects: 20
Study 20528908 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment in vitro
Number of subjects: 20
Study 18271279 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified orange beverage
Number of subjects: 10
Study 18271279 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 10
Study 15101020 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (target INR 2.5-3.0)
Number of subjects: 1587
Study 15101020 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 162 mg
Number of subjects: 1587
Study 15101020 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg
Number of subjects: 1587
Study 15101020 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1587
Study 15101020 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1587
Study 15101020 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1587
Study 12234946 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg for 14 days
Number of subjects: 40
Study 12234946 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 40
Study 12234946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9836113 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete alcohol withdrawal after 7 and 14 days
Number of subjects: 51
Study 7917697 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR pacing mode
Number of subjects: 29
Study 7917697 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI 85 pacing mode
Number of subjects: 29
Study 7917697 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity pacemakers
Number of subjects: 29
Study 7917697 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual sensor pacemakers
Number of subjects: 29
Study 7917697 — intervention group
Group type: COMPARATOR
Intervention: Control population
Number of subjects: 29
Study 2510530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g single preoperative dose)
Number of subjects: 1451
Study 2510530 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (four 2-g doses)
Number of subjects: 1451
Study 4838915 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate
Number of subjects: 80
Study 4838915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30914169 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent girls' agency
Number of subjects: 3186
Study 27873516 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose EC‐MPS with low dose CsA
Number of subjects: 140
Study 27873516 — intervention group
Group type: COMPARATOR
Intervention: Standard dose CsA with low dose EC‐MPS
Number of subjects: 140
Study 27873516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 25928131 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative treatment (IT)
Number of subjects: 120
Study 25928131 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic acupuncture (TA)
Number of subjects: 120
Study 25928131 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 120
Study 23867209 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic therapy (7 days preoperative and 10 days postoperative)
Number of subjects: 48
Study 23867209 — intervention group
Group type: COMPARATOR
Intervention: Control group without synbiotic therapy
Number of subjects: 48
Study 23867209 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic therapy
Number of subjects: 48
Study 22089773 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Carnitine supplementation (1 g/dose, intravenously three times a week after each HD session)
Number of subjects: 35
Study 22089773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no L-Carnitine supplementation)
Number of subjects: 35
Study 19933081 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin 40 mg/m(2) intravenously every 28 days
Number of subjects: 102
Study 19933081 — intervention group
Group type: COMPARATOR
Intervention: Weekly docetaxel 36 mg/m(2) intravenously days 1, 8, and 15, repeated every 28 days
Number of subjects: 102
Study 17086087 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fitting procedure
Number of subjects: 18
Study 17086087 — intervention group
Group type: COMPARATOR
Intervention: ECAP based fitting procedure
Number of subjects: 18
Study 15001930 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone for 3 days
Number of subjects: 59
Study 11316896 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Blood (WB)
Number of subjects: 24
Study 11316896 — intervention group
Group type: COMPARATOR
Intervention: RBCs and FFP (RCP)
Number of subjects: 24
Study 9374563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 5 mg/kg
Number of subjects: 285
Study 9374563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg
Number of subjects: 285
Study 9374563 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 12 mg/kg
Number of subjects: 285
Study 9374563 — intervention group
Group type: EXPERIMENTAL
Intervention: Children hospitalized with dehydration
Number of subjects: 285
Study 7955970 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal (42 kJ, kg-1 lean body mass) during pregnancy
Number of subjects: 10
Study 7955970 — intervention group
Group type: COMPARATOR
Intervention: Resting energy expenditure during pregnancy
Number of subjects: 10
Study 7955970 — intervention group
Group type: COMPARATOR
Intervention: Resting energy expenditure after pregnancy
Number of subjects: 10
Study 7955970 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial thermogenesis after pregnancy
Number of subjects: 10
Study 7955970 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance during pregnancy (0.05 U kg-1 intravenously)
Number of subjects: 10
Study 7955970 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance after pregnancy (0.05 U kg-1 intravenously)
Number of subjects: 10
Study 3790639 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone, 300 mg/day
Number of subjects: 0
Study 3790639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31206613 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 50 mg/kg IV plus 500 mg oral twice per day for 3 months
Number of subjects: 42
Study 31206613 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 42
Study 28729158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus abacavir and lamivudine (single-tablet regimen)
Number of subjects: 499
Study 28729158 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine (three-tablet combination)
Number of subjects: 499
Study 28729158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus abacavir and lamivudine
Number of subjects: 499
Study 28729158 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine
Number of subjects: 499
Study 25908245 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 37
Study 25908245 — intervention group
Group type: COMPARATOR
Intervention: Conventional saw
Number of subjects: 37
Study 23732643 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of supervised resistive exercise (for young individuals)
Number of subjects: 20
Study 23732643 — intervention group
Group type: COMPARATOR
Intervention: 4 weeks of supervised resistive exercise (for older individuals)
Number of subjects: 20
Study 23732643 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of supervised resistive exercise (for both groups)
Number of subjects: 20
Study 21823280 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding combined vessel pricking therapy (group A)
Number of subjects: 86
Study 21823280 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Sulfasalazine (SASP) (group B)
Number of subjects: 86
Study 20082923 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 1616
Study 20082923 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 1616
Study 16768632 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release dexmethylphenidate (d-MPH-ER) 20 mg/day
Number of subjects: 54
Study 16768632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 12781282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel intraocular lens (IOL)
Number of subjects: 37
Study 12781282 — intervention group
Group type: COMPARATOR
Intervention: Silicone intraocular lens (IOL)
Number of subjects: 37
Study 11152929 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 50
Study 11152929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet containing 1-mg folic acid, 1-mg B12, and 25-mg B6
Number of subjects: 50
Study 11152929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet containing 2.5-mg folic acid, 1-mg B12, and 25-mg B6
Number of subjects: 50
Study 9329288 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 394
Study 9329288 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 394
Study 9329288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study 8378772 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of chicken type II collagen for 3 months
Number of subjects: 60
Study 8378772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2876024 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric ulcer follow-up after an average of 21.2 months
Number of subjects: 110
Study 2876024 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal ulcer follow-up after an average of 35.6 months
Number of subjects: 110
Study 2876024 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic recurrences in gastric and duodenal ulcers
Number of subjects: 110
Study 2876024 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect of smoking on recurrence rates
Number of subjects: 110
Study 28110590 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniotomy (artificial rupture of membranes when cervical dilation was at 3 cm)
Number of subjects: 200
Study 28110590 — intervention group
Group type: COMPARATOR
Intervention: Standard amniotomy (membranes left to rupture spontaneously)
Number of subjects: 200
Study 28110590 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniotomy
Number of subjects: 200
Study 28110590 — intervention group
Group type: COMPARATOR
Intervention: Standard amniotomy
Number of subjects: 200
Study 27058753 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM plus S-1 (GEM-S-1)
Number of subjects: 75
Study 27058753 — intervention group
Group type: COMPARATOR
Intervention: GEM
Number of subjects: 75
Study 27058753 — intervention group
Group type: COMPARATOR
Intervention: S-1
Number of subjects: 75
Study 27058753 — intervention group
Group type: EXPERIMENTAL
Intervention: CA19-9<466 U/ml
Number of subjects: 75
Study 27058753 — intervention group
Group type: COMPARATOR
Intervention: CA19-9>571 U/ml
Number of subjects: 75
Study 24156957 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 750
Study 24156957 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene
Number of subjects: 750
Study 24156957 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 750
Study 24156957 — intervention group
Group type: EXPERIMENTAL
Intervention: Men's characteristics
Number of subjects: 750
Study 22770683 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 75
Study 22770683 — intervention group
Group type: COMPARATOR
Intervention: Control group (medical treatment)
Number of subjects: 75
Study 20043983 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (inflammatory challenge)
Number of subjects: 0
Study 20043983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17726317 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 790
Study 17726317 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete revascularization
Number of subjects: 790
Study 15848983 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer containing urea applied twice daily for 20 days
Number of subjects: 30
Study 15848983 — intervention group
Group type: COMPARATOR
Intervention: Control (other forearm without moisturizer)
Number of subjects: 30
Study 15848983 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch tests with 0%, 0.5% and 2% NiSO4 in petrolatum
Number of subjects: 30
Study 12877666 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 2.25 microg/kg, s.c., once weekly for 12 weeks
Number of subjects: 344
Study 12877666 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 344
Study 12877666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study 11895470 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (3 units of ethanol daily for 1 week)
Number of subjects: 21
Study 11895470 — intervention group
Group type: COMPARATOR
Intervention: No alcohol (abstinence for 1 week)
Number of subjects: 21
Study 9821922 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperiosteal dissection without release
Number of subjects: 8
Study 9821922 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperiosteal dissection with release
Number of subjects: 8
Study 9821922 — intervention group
Group type: COMPARATOR
Intervention: Subgaleal dissection
Number of subjects: 8
Study 9821922 — intervention group
Group type: EXPERIMENTAL
Intervention: All dissection methods
Number of subjects: 8
Study 7907261 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH (150 IU twice a week for 2 weeks, then 150 IU FSH and 250 IU hCG twice a week for 4 weeks)
Number of subjects: 22
Study 7907261 — intervention group
Group type: COMPARATOR
Intervention: hCG (250 IU twice a week for 6 weeks)
Number of subjects: 22
Study 2644151 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 25 micrograms t.i.d. for 7 days
Number of subjects: 12
Study 2644151 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms t.i.d. for 7 days
Number of subjects: 12
Study 2644151 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (both dosages)
Number of subjects: 12
Study 31093742 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper retreatment instruments in combination with gutta‐percha solvent
Number of subjects: 90
Study 31093742 — intervention group
Group type: COMPARATOR
Intervention: ProTaper retreatment instruments without solvent
Number of subjects: 90
Study 31619767 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV transformed B cells
Number of subjects: 3
Study 31619767 — intervention group
Group type: EXPERIMENTAL
Intervention: CD40L-activated B cells
Number of subjects: 3
Study 29165767 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA insertion anesthesia
Number of subjects: 76
Study 29165767 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation
Number of subjects: 76
Study 25939678 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% topical glycopyrrolate wipes
Number of subjects: 36
Study 25939678 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% topical glycopyrrolate wipes
Number of subjects: 36
Study 25939678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 36
Study 23572499 — intervention group
Group type: EXPERIMENTAL
Intervention: AF±AFL ablation (n=182)
Number of subjects: 360
Study 23572499 — intervention group
Group type: COMPARATOR
Intervention: AFL ablation only (n=178)
Number of subjects: 360
Study 21705552 — intervention group
Group type: EXPERIMENTAL
Intervention: High hydrostatic pressure processing (HPP) at 600 MPa at 6°C for 5 min
Number of subjects: 44
Study 21705552 — intervention group
Group type: COMPARATOR
Intervention: High hydrostatic pressure processing (HPP) at 400 MPa at 6°C or 25°C
Number of subjects: 44
Study 21705552 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HPP treatment)
Number of subjects: 44
Study 21705552 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte shift in infected subjects
Number of subjects: 44
Study 19379093 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood stabilizers (except divalproic acid)
Number of subjects: 0
Study 19379093 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproic acid and carbamazepine
Number of subjects: 0
Study 19379093 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0